These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18317497)

  • 1. How should PSA screening efforts be focused to prevent underdiagnosis and overdiagnosis of prostate cancer?
    Pelzer AE; Horninger W
    Nat Clin Pract Urol; 2008 Apr; 5(4):172-3. PubMed ID: 18317497
    [No Abstract]   [Full Text] [Related]  

  • 2. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
    Telesca D; Etzioni R; Gulati R
    Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer.
    Loeb S; Carter HB
    Urol Oncol; 2009; 27(6):583-4. PubMed ID: 19879470
    [No Abstract]   [Full Text] [Related]  

  • 4. What to do with an abnormal PSA test.
    Loeb S; Catalona WJ
    Oncologist; 2008 Mar; 13(3):299-305. PubMed ID: 18378540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
    Ito K
    Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate specific antigen (PSA)-based screening.
    Suzuki H; Flanigan RC; Okuyama A;
    Int J Urol; 2008 Sep; 15(9):757-62. PubMed ID: 18786202
    [No Abstract]   [Full Text] [Related]  

  • 7. [PSA based screening for prostatic cancer].
    Johansen TE
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2612-4. PubMed ID: 19023357
    [No Abstract]   [Full Text] [Related]  

  • 8. PSA and prostate cancer screening: the challenge of the new millennium.
    Bjartell A
    Eur Urol; 2007 Nov; 52(5):1284-6. PubMed ID: 17720305
    [No Abstract]   [Full Text] [Related]  

  • 9. Upcoming evidences on prostate-specific antigen-based screening for men at risk of prostate cancer.
    Boscolo-Berto R
    Int J Urol; 2009 Sep; 16(9):711. PubMed ID: 19769655
    [No Abstract]   [Full Text] [Related]  

  • 10. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan.
    Ito K; Kakehi Y; Naito S; Okuyama A;
    Int J Urol; 2008 Sep; 15(9):763-8. PubMed ID: 18786203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Based on current knowledge the introduction of the PSA screening for prostatic cancer is unethical].
    Krantz I; Sachs L; Ahlberg BM; Nordin P; Nilstun T
    Lakartidningen; 2005 Sep 5-11; 102(36):2498-500. PubMed ID: 16196436
    [No Abstract]   [Full Text] [Related]  

  • 12. Screening for prostate cancer.
    Brawley OW; Ankerst DP; Thompson IM
    CA Cancer J Clin; 2009; 59(4):264-73. PubMed ID: 19564245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the PSA test useless?
    Kirby R; Moul JW
    Prostate Cancer Prostatic Dis; 2004; 7(4):271-2. PubMed ID: 15592438
    [No Abstract]   [Full Text] [Related]  

  • 14. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
    Crawford ED; Abrahamsson PA
    Eur Urol; 2008 Aug; 54(2):262-73. PubMed ID: 18556114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Opportunity for a systematic screening of prostatic cancer by determining prostate specific antigen levels].
    Cuzin B; Maisonneuve H; Thoral F; Charvet-Protat S
    Prog Urol; 2000 Feb; 10(1):124-7. PubMed ID: 10785932
    [No Abstract]   [Full Text] [Related]  

  • 16. The relationship between prostate cancer knowledge and beliefs and intentions to attend PSA screening among at-risk men.
    Hevey D; Pertl M; Thomas K; Maher L; Chuinneagáin SN; Craig A
    Patient Educ Couns; 2009 Feb; 74(2):244-9. PubMed ID: 18848753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cruciferous vegetables and prostate cancer risk: confounding by PSA screening.
    Kristal AR; Stanford JL
    Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1265. PubMed ID: 15247142
    [No Abstract]   [Full Text] [Related]  

  • 18. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 19. Rural residence and prostate cancer screening with prostate-specific antigen.
    Stamatiou K; Skolarikos A
    Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining increased future risk for prostate cancer: evidence from a population based screening cohort.
    Schröder FH; Roobol MJ; Andriole GL; Fleshner N
    J Urol; 2009 Jan; 181(1):69-74; discussion 74. PubMed ID: 19012915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.